|
Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study. |
|
|
Stock and Other Ownership Interests - CellGenix (I) |
Consulting or Advisory Role - Affimed Therapeutics; AVEO; Calithera Biosciences; Eisai; Exelixis; Genentech; Merck; Oncorena; OnQuality Pharmaceuticals; Pfizer |
Research Funding - Pfizer |
|
(OPTIONAL) Uncompensated Relationships - Aravive; BMS; Genentech/Roche |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen |
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen |
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche |
|
Bradley Alexander McGregor |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Nextar; Pfizer; Seattle Genetics/Astellas |
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Pfizer/EMD Serono (Inst); Seattle Genetics/Astellas (Inst) |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Genmab; MSD; Seagen |
Honoraria - Advanced Accelerator Applications/Novartis; Apogepha; AstraZeneca; Bristol-Myers Squibb; ClinSol; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Nanobiotix; Novartis; Ono Pharmaceutical; Pfizer; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; Cor2Ed; Debiopharm Group; Eisai; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Onkowissen; Pfizer |
Research Funding - Amgen (Inst); BMS (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Pfizer |
|
|
Consulting or Advisory Role - Merck |
Research Funding - BioNTech (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Genentech/Roche (Inst); Merck (Inst); Peloton Therapeutics (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Seattle Genetics/Astellas (Inst); Sillajen (Inst); Tizona Therapeutics, Inc. (Inst); Tocagen (Inst); Trishula Therapeutics (Inst); Vyriad (Inst) |
Patents, Royalties, Other Intellectual Property - UpToDate |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Merck KGaA; MSD Oncology; Pfizer |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD Oncology; Pfizer |
|
|
Consulting or Advisory Role - Astellas Pharma; BMS; Ipsen |
|
|
Stock and Other Ownership Interests - ICON Cancer Care; Immutep |
Honoraria - Ipsen; MSD Oncology |
Consulting or Advisory Role - BMS; GlaxoSmithKline; Janssen Oncology; MSD |
Speakers' Bureau - AstraZeneca/MedImmune; BMS; Ipsen; Janssen; MSD Oncology |
Research Funding - BeiGene (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
|
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
|
|
Employment - Eisai; Eisai |
Travel, Accommodations, Expenses - Eisai; Eisai |
|
|
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |